|Videos|June 16, 2017

How Effective Are C. difficile Bundled Approaches?

Gonzalo Bearman, MD, MPH, shares a few things to keep in mind when using bundled approaches against C. difficile.

Gonzalo Bearman, MD, MPH, Professor of Medicine and Hospital Epidemiologist, Virginia Commonwealth University, shares a few things to keep in mind when using bundled approaches against C. difficile.

Interview Transcript (slightly modified for readability)

“I think that bundled approaches have their limitations. I think that the key point here is that bundled approaches need to be done with higher reliability and after assessing the reliability and the effectiveness of that bundled approach. If things aren’t improving, the desired outcomes aren’t where they should be, and the processes aren’t where they should be, then we need to rethink it.

So, my approach is, we start with a bundled strategy, and if it’s not working, we need to be nimble, and change our strategy accordingly. I’m not saying that we should never do active detection and isolation for [Clostridium] C. difficile; I think it’s reasonable, particularly if your bundled approaches are failing, and if you’re certain that you’re doing all of the bundled elements within that approach properly.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.